PPBT · Purple Biotech Ltd.
Market Cap
$1.77M
Shares
1.63M
Volume · Oct 21
9876
Avg daily vol (3M)
1.26M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.15
Open$1.09
Day$1.09–1.15
52W close$1.08–10.60
Avg vol 30d41K
Short int18K · 1.1% float · 1.0d
Short vol1%
DataJan 2020–Oct 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+0.0%
Year over year
Operating margin
-1,261.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+259.5%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.1%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−64%
below
Price vs 50-day avg
−25%
below
RSI (14)
32
neutral
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−23%
trailing
6-month return
−72%
trailing
YTD return
−83%
this year
Relative strength
−80%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-13% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.11% of float · ▼ -77.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
13 holders — mid 3-yr range
Squeeze score
37
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
122%
annualized · 1-yr
Max drawdown
−90%
past year
ATR
10.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−64%
Bearish
Price vs 50-day avg
−25%
Bearish
RSI (14)
32
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-13% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.11% of float · ▼ -77.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
13 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 1%
Range high $11
vs 200-day avg -64%
vs 50-day avg -25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PPBT
this stock
Purple Biotech Ltd.
|
$1.77M | — | — | — | 1.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.39B | +15.7% | +46.2% | 30.2 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +733.5% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.4% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PPBT | -6.5% | -22.6% | -72.2% | -24.3% | -82.5% |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | -7.0% | -23.3% | -79.7% | -25.7% | -95.9% |